Clinical trials · District of Columbia
Pancreatic Ductal Adenocarcinoma clinical trials in District of Columbia
We’re tracking 9 recruiting pancreatic ductal adenocarcinoma studies with a site in District of Columbia — including Phase 1, Phase 1/Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in District of Columbia
- NCT05254171RecruitingPhase 2/Phase 3
Trial adds SBP-101 to standard chemo for pancreatic cancer
This trial studies whether adding SBP-101 to standard chemotherapy (gemcitabine plus nab-paclitaxel) can improve outcomes in people with metastatic pancreatic cancer. You may be eligible if you have not yet started treatment for metastatic disease and meet other health and test requirements.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06958328RecruitingPhase 3
Testing higher dose radiation for locally advanced pancreatic cancer
This trial tests if a higher dose of radiation therapy can help people with locally advanced pancreatic cancer after they've had 4–6 months of chemotherapy. It aims to improve cancer control without significantly increasing side effects.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Washington D.C., District of ColumbiaAges 1–30 - NCT06989437RecruitingPhase 2/Phase 3
Study of Ponsegromab for Pancreatic Cancer with Weight Loss
This study tests an experimental drug called ponsegromab for people with advanced pancreatic cancer who experience severe weight loss and fatigue. It aims to see if the drug can help improve weight and energy levels while you continue standard chemotherapy.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06428409RecruitingPhase 1/Phase 2
A study of MK-2870 for several gastrointestinal cancers
This trial is testing a new drug called MK-2870, alone or with other treatments, for people with advanced colorectal, pancreatic, or bile duct cancer. It aims to see if the drug can help shrink or control the cancer.
Washington D.C., District of ColumbiaAges 18 years+
Pancreatic Ductal Adenocarcinoma trials by city in District of Columbia
Where these studies are running in District of Columbia
Institutions with a site for the recruiting pancreatic ductal adenocarcinoma studies listed above.
- Georgetown University Medical Center · 3 studies
- Children's National Medical Center
- Johns Hopkins Medicine
- MedStar Georgetown University Hospital
- MedStar Washington Hospital Center
- Novartis Investigative Site
- Sibley Memorial Hospital
What taking part in a pancreatic ductal adenocarcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Pancreatic Ductal Adenocarcinoma trials in other states
Common questions
- Are there pancreatic ductal adenocarcinoma clinical trials in District of Columbia?
- Yes. We're currently tracking 9 recruiting pancreatic ductal adenocarcinoma studies with a site in District of Columbia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a pancreatic ductal adenocarcinoma study in District of Columbia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in District of Columbia to take part?
- Not necessarily. These studies have a site in District of Columbia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a pancreatic ductal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New pancreatic ductal adenocarcinoma studies open in District of Columbia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.